TY - JOUR

T1 - Intralesional triamcinolone for flares of hidradenitis suppurativa (HS)

T2 - A case series

AU - Riis, Peter Theut

AU - Boer, Jurr

AU - Prens, Errol P

AU - Saunte, Ditte M L

AU - Deckers, Inge Evon

AU - Emtestam, Lennart

AU - Sartorius, Karin

AU - Jemec, Gregor B E

N1 - Copyright © 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

PY - 2016/12

Y1 - 2016/12

N2 - BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the hair follicle. Standard practice of managing acute flares with corticosteroid injection lacks scientific evidence.OBJECTIVE: We sought to assess the outcomes of routine treatment using intralesional triamcinolone (triamcinolone acetonide 10 mg/mL) in the management of acute flares in HS.METHODS: This was a prospective case series evaluating the effect of intralesional corticosteroids for alleviation of acute flares in HS. Physician- and patient-reported outcomes were noted.RESULTS: Significant reductions in physician-assessed erythema (median score from 2-1, P < .0001), edema (median score from 2-1, P < .0001), suppuration (median score from 2-1, P < .0001), and size (median score from 3-1, P < .0001) was demonstrated at follow-up. A significant difference in patient-reported pain visual analog scale scores occurred after 1 day (from 5.5-2.3, P < .005) and from day 1 to day 2 (from 2.3-1.4, P < .002).LIMITATIONS: Small study size, open single-arm design, and short follow-up time are the limitations of this study.CONCLUSION: Intralesional injection of corticosteroids is perceived as beneficial by physicians and patients in the management of HS flares by reducing pain after 1 day and signs of inflammation approximately 7 days later.

AB - BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the hair follicle. Standard practice of managing acute flares with corticosteroid injection lacks scientific evidence.OBJECTIVE: We sought to assess the outcomes of routine treatment using intralesional triamcinolone (triamcinolone acetonide 10 mg/mL) in the management of acute flares in HS.METHODS: This was a prospective case series evaluating the effect of intralesional corticosteroids for alleviation of acute flares in HS. Physician- and patient-reported outcomes were noted.RESULTS: Significant reductions in physician-assessed erythema (median score from 2-1, P < .0001), edema (median score from 2-1, P < .0001), suppuration (median score from 2-1, P < .0001), and size (median score from 3-1, P < .0001) was demonstrated at follow-up. A significant difference in patient-reported pain visual analog scale scores occurred after 1 day (from 5.5-2.3, P < .005) and from day 1 to day 2 (from 2.3-1.4, P < .002).LIMITATIONS: Small study size, open single-arm design, and short follow-up time are the limitations of this study.CONCLUSION: Intralesional injection of corticosteroids is perceived as beneficial by physicians and patients in the management of HS flares by reducing pain after 1 day and signs of inflammation approximately 7 days later.

KW - Adult

KW - Anti-Inflammatory Agents

KW - Edema

KW - Erythema

KW - Hidradenitis Suppurativa

KW - Humans

KW - Injections, Intralesional

KW - Pain

KW - Prospective Studies

KW - Severity of Illness Index

KW - Suppuration

KW - Treatment Outcome

KW - Triamcinolone

KW - Journal Article

KW - Multicenter Study

U2 - 10.1016/j.jaad.2016.06.049

DO - 10.1016/j.jaad.2016.06.049

M3 - Journal article

C2 - 27692735

VL - 75

SP - 1151

EP - 1155

JO - American Academy of Dermatology. Journal

JF - American Academy of Dermatology. Journal

SN - 0190-9622

IS - 6

ER -